Determining the effect of low-dose isotretinoin on proliferative vitreoretinopathy: the DELIVER trial.

Purpose: To examine the effect of low-dose, oral isotretinoin in lowering the risk of proliferative vitreoretinopathy (PVR) following rhegmatogenous retinal detachment (RRD) repair.

Methods: Prospective, open label, dual-cohort study with pathology-matched historical controls. The prospective experimental arms included two cohorts, composed of 51 eyes with recurrent PVR-related RRD and 58 eyes with primary RRD associated with high-risk features for developing PVR.

Choroidal vascular analysis in myopic eyes: evidence of foveal medium vessel layer thinning.

Purpose: To analyse morphologic features of the choroid in Non-pathological myopic eyes using spectral-domain (SD) optical coherence tomography (OCT).

Methods: Retrospective analysis of enhanced depth SD-OCT images of Non-pathological myopic eyes in comparison with age-matched healthy controls was performed. Choroidal thickness (CT) and large choroidal vessel thickness (LCVT) were measured at the fovea, 750 µm nasally from fovea (N) and 750 µm temporally (T) from fovea.

Subfoveal Choroidal Vascularity in Myopia: Evidence From Spectral-Domain Optical Coherence Tomography.

Background And Objective: To evaluate subfoveal choroidal vascularity in eyes with myopia in comparison to age-matched healthy subjects.

Patients And Methods: Retrospective analysis of single foveal enhanced depth imaging optical coherence tomography (EDI-OCT) scans of 30 eyes with myopia (axial length greater than 25 mm). Subfoveal choroidal vascularity was evaluated by calculating vessel-area-to-stromal-area ratio using a previously validated automated algorithm.

Neovascular events in eyes with central retinal vein occlusion undergoing serial bevacizumab or ranibizumab intravitreal injections: a retrospective review.

Purpose: To characterize the onset and type of neovascular events in eyes with central retinal vein occlusion (CRVO) undergoing serial anti-VEGF therapy.

Methods: Consecutive eyes undergoing serial intravitreal bevacizumab or ranibizumab injections for treatment of CME secondary to CRVO were identified. Pertinent data was retrospectively collected and included type and onset of the neovascular event, and the treatment free interval from last injection until the neovascular event.

Pars plana vitrectomy and scleral buckle versus pars plana vitrectomy alone for patients with rhegmatogenous retinal detachment at high risk for proliferative vitreoretinopathy.

Purpose: To compare using pars plana vitrectomy (PPV) combined with a scleral buckle versus primary vitrectomy alone in patients with rhegmatogenous retinal detachment at high risk for postoperative proliferative vitreoretinopathy (PVR).

Methods: Six hundred and seventy-eight patients were identified from billing data as having rhegmatogenous retinal detachment between April 1, 2010 and August 1, 2012. Patients were considered at high risk for PVR if they presented with retinal detachment in 2 or more quadrants, retinal tears >1 clock hour, preoperative PVR, or vitreous hemorrhage.

Outcomes of scleral buckle removal with and without concurrent prophylactic laser retinopexy.

Objective: To present the outcomes of scleral buckle (SB) removal with and without concurrent prophylactic laser retinopexy.

Design: Retrospective, interventional case series.

Participants: Eighty-seven eyes of 87 patients who had SB removal after primary rhegmatogenous retinal detachment repair.

Postoperative vitreous hemorrhage after diabetic 23-gauge pars plana vitrectomy.

Purpose: To report the frequency of postoperative vitreous hemorrhage (VH) in eyes that underwent primary 23-gauge pars plana vitrectomy (PPV) for nonclearing VH resulting from proliferative diabetic retinopathy, as well as associated risk factors.

Design: Retrospective, consecutive, interventional case series.

Setting: Institutional (Retina Service of Wills Eye Institute).